Combined Chemoradiation Therapy With Twice-Weekly Gemcitabine and Cisplatin for Organ Preservation in Muscle-Invasive Bladder Cancer: Long-Term Results of a Phase 1 Trial.: Conservative bladder cancer treatment by Azria, David et al.
Combined Chemoradiation Therapy With Twice-Weekly
Gemcitabine and Cisplatin for Organ Preservation in
Muscle-Invasive Bladder Cancer: Long-Term Results of
aPhase 1 Trial.
David Azria, Olivier Riou, Xavier Rebillard, Simon Thezenas, Rodolphe
Thuret, Pascal Fenoglietto, Damien Pouessel, Stephane Culine
To cite this version:
David Azria, Olivier Riou, Xavier Rebillard, Simon Thezenas, Rodolphe Thuret, et al.. Com-
bined Chemoradiation Therapy With Twice-Weekly Gemcitabine and Cisplatin for Organ
Preservation in Muscle-Invasive Bladder Cancer: Long-Term Results of aPhase 1 Trial.: Con-
servative bladder cancer treatment. International Journal of Radiation Oncology - Biology -
Physics, Elsevier, 2014, 88 (4), pp.853-9. <10.1016/j.ijrobp.2013.11.016>. <inserm-00924350>
HAL Id: inserm-00924350
http://www.hal.inserm.fr/inserm-00924350
Submitted on 6 Jan 2014
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

                             Elsevier Editorial System(tm) for International Journal of Radiation 
Oncology*Biology*Physics 
                                  Manuscript Draft 
 
 
Manuscript Number: ROB-D-13-01170R2 
 
Title: Combined Chemoradiotherapy with Twice Weekly Gemcitabine and Cisplatin for Organ 
Preservation in Muscle-invasive Bladder Cancer: Long-term Results of a Phase I Trial  
 
Article Type: Full Length Article 
 
Section/Category: Clinical Investigation - Genitourinary Cancers 
 
Corresponding Author: Prof. David Azria, M.D., Ph.D. 
 
Corresponding Author's Institution: CRLC Val d'Aurelle 
 
First Author: David Azria, M.D., Ph.D. 
 
Order of Authors: David Azria, M.D., Ph.D.; Olivier  Riou; Xavier Rebillard; Simon  Thezenas; Rodolphe 
Thuret; Pascal Fenoglietto; Damien Pouessel; Stephane Culine 
 
Abstract: Purpose: Concomitant treatment with radiotherapy and cisplatin (CDDP) remains the gold 
standard for bladder preservation in case of muscle-invasive bladder cancer (MIBC). We present the 
long-term results of a phase I clinical trial to assess the association of gemcitabine (given twice/week) 
with CDDP and radiotherapy in this setting.  
Methods and Materials: Patients with pT2-pT4 N0 M0 MIBC without hydronephrosis or diffuse 
carcinoma in situ were enrolled in this study. After maximal transurethral resection of the bladder 
tumor, patients received concomitantly radiotherapy (63 Gy in 1.8 fractions) and chemotherapy (20 
mg CDDP /m²/day over 4 days every 21 days; and gemcitabine twice a week). The starting dose of 
gemcitabine was 15 mg/m² with dose escalation to 20, 25 and 30 mg/m². The primary endpoint was 
the determination of the maximum tolerated dose (MTD). Secondary endpoints included the 
assessment of toxicity and tumor control. 
Results: Fourteen patients were enrolled. Dose-limiting toxicity (DLT) occurred in two patients treated 
with 30 mg/m² gemcitabine (grade 4 thrombocytopenia and severe impairment of the WHO 
performance status, respectively). Nine patients received the complete chemo-radiotherapy protocol. 
The recommended dose of gemcitabine was 25 mg/m². The median follow-up was 53 months, and the 
overall and disease-specific survival rates were 62% and 77% at 5 years, respectively. Among the 
patients who received the complete treatment, bladder-intact survival was 76% at 5 years and the 
median overall survival 69.6 months. 
Conclusions: This regimen was well-tolerated. The gemcitabine MTD was 25 mg/m². Bladder 
preservation and disease control were promising. A multicenter phase II randomized trial is ongoing. 
 
 
Suggested Reviewers:  
 
Opposed Reviewers:  
 
 
  
Montpellier November, 6th 2013 
Editorial Office 
International Journal of Radiation Oncology * Biology * Physics 
8280 Willow Oaks Corporate Drive, Suite 500 
Fairfax, VA 22031 
USA 
 
 
Dear Editor, 
 
Here is the second revised version of our manuscript entitled “Combined 
Chemoradiotherapy with Twice Weekly Gemcitabine and Cisplatin for Organ Preservation in 
Muscle-invasive Bladder Cancer: Long-term Results of a Phase I Trial” (ROB-D-13-01170).  
The manuscript has been review and corrected by the team of the Mount Sinai in New York.  
 
We hope that all minor grammatical errors are now corrected. 
 
Sincerely yours, 
 
 Pr David AZRIA 
*Detailed Response to Reviewers (No Author Details)
1 
 
Combined Chemoradiotherapy with Twice Weekly Gemcitabine and 
Cisplatin for Organ Preservation in Muscle-invasive Bladder Cancer: 
Long-term Results of a Phase I Trial  
 
David Azria, MD, PhD,‡,§,#,* Olivier Riou, MD,‡,#  Xavier Rebillard, MD,$ Simon 
Thezenas, MSc,Ω Rodolphe Thuret, MD, PhD,£ Pascal Fenoglietto, MSc,‡ Damien 
Pouessel, MD,¥ and Stephane Culine, MD, PhD¥ 
 
‡Department of Radiation Oncology and Radiophysics Unit, Montpellier Cancer Institute (ICM), Montpellier, France; 
§INSERM, U896, IRCM, Montpellier, France; $Department of Urology, Clinique Beausoleil, Montpellier, France; 
ΩBiostatistics Unit, Montpellier Cancer Institute, Montpellier, France;  £Department of Urology, Montpellier University 
Hospital, Montpellier, France; ¥Department of Medical Oncology, AP-HP Saint-Louis, Paris, France 
 
* Reprint requests to: David Azria, MD, PhD, Department of Radiation Oncology, Montpellier 
Cancer Institute (ICM), 34298 Montpellier Cedex 5, France. Tel: + 33 4 67 61 31 32; Fax: + 
33 4 67 61 31 35; E-mail : david.azria@icm.unicancer.fr 
 
#contributed equally to this work and should be considered as joint first authors 
Presented in part at the American Society of Clinical Oncology Genito-Urinary (ASCO GU) 
Annual Meeting, San Francisco in 2010 and at the 53th ASTRO Annual Meeting, Boston in 
2012.  
 
Conflict of interest: none  
 
Running title: Conservative bladder cancer treatment 
 
*Title Page (WITH Author Details)
1 
 
Summary 
Concomitant radiotherapy and cisplatin (CCRT) remains the gold standard in the bladder 
preservation strategy in case of muscle invasive bladder cancer. We evaluated the role of 
adding gemcitabine given twice weekly to the standard CCRT. Among patients that received 
complete treatment, bladder-intact survival was 76% at 5 years and median overall survival 
was 69.6 months. The maximum-tolerated dose (MTD) of gemcitabine was 25 mg/m². 
Bladder preservation and disease control were promising. 
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1 
 
Combined Chemo-radiotherapy with Twice-weekly Gemcitabine and 
Cisplatin for Organ Preservation in Muscle-invasive Bladder Cancer: 
Long-term Results of a Phase I Trial  
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Summary 
Concomitant treatment with cisplatin and radiotherapy (CCRT) remains the gold standard for 
bladder preservation in the case of muscle-invasive bladder cancer. We evaluated the benefit 
of adding gemcitabine given twice a week to the standard CCRT. Among the patients who 
received the complete treatment, bladder-intact survival was 76% at 5 years and the median 
overall survival was 69.6 months. The gemcitabine maximum tolerated dose was 25 mg/m². 
Bladder preservation and disease control were promising. 
 
Abstract 
Purpose: Concomitant treatment with radiotherapy and cisplatin (CDDP) remains the gold 
standard for bladder preservation in the case of muscle-invasive bladder cancer (MIBC). We 
present the long-term results of a phase I clinical trial to assess the association of twice-
weekly gemcitabine with CDDP and radiotherapy in this setting.  
Methods and Materials: Patients with pT2-pT4 N0 M0 MIBC without hydronephrosis or 
diffuse carcinoma in situ were enrolled in this study. After maximal transurethral resection of 
the bladder tumor, patients received concomitantly radiotherapy (63 Gy in 1.8 fractions) and 
chemotherapy (20 mg CDDP /m²/day over 4 days every 21 days; and gemcitabine twice a 
week). The starting dose of gemcitabine was 15 mg/m² with dose escalation to 20, 25 and 30 
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mg/m². The primary endpoint was the determination of the maximum tolerated dose (MTD). 
Secondary endpoints included the assessment of toxicity and tumor control. 
Results: Fourteen patients were enrolled. Dose-limiting toxicity (DLT) occurred in two 
patients treated with 30 mg/m² gemcitabine (grade 4 thrombocytopenia and severe 
impairment of the WHO performance status, respectively). Nine patients received the 
complete chemo-radiotherapy protocol. The recommended dose of gemcitabine was 25 
mg/m². The median follow-up was 53 months, and the overall and disease-specific 5-year 
survival rates were 62% and 77% at 5 years, respectively. Among the patients who received 
the complete treatment, bladder-intact survival was 76% at 5 years and the median overall 
survival was 69.6 months. 
Conclusions: This regimen was well-tolerated. The gemcitabine MTD was 25 mg/m². 
Bladder preservation and disease control were promising. A multicenter phase II randomized 
trial is ongoing. 
 
Keywords: bladder cancer; chemo-radiotherapy; gemcitabine; cisplatin; organ preservation 
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Introduction 
 
Concurrent chemo-radiotherapy (CCRT) for muscle-invasive transitional cell bladder cancer 
(MIBC) is an acceptable option for patients who are medically unfit for radical surgery as 
well as for patients initially selected for cystectomy. The standard CCRT includes a cisplatin 
(CDDP)-containing regimen and is associated with cystectomy-free survival rates between 
42% and 55% at 5 years, depending on the initial tumor stage (1-6).  
Gemcitabine has been shown to be active ineffective in treating bladder cancer in combination 
with CDDP in neoadjuvant and metastatic settings (7, 8). In addition, gemcitabine has 
significant radiosensitizing activity in various cancer cell lines (9, 10), including those derived 
from bladder tumors (11). The effectiveness of gemcitabine-based CCRT has been widely 
reported for many different epithelial tumors (12, 13). Gemcitabine sensitizing activity occurs 
at sub-cytotoxic doses, and the mechanism involves depletion of the deoxyribonucleoside 
triphosphate pools, particularly deoxyadenosine triphosphate (dATP) (14). Consecutive 
studies confirmed that weekly doses ranging from 150 to 450 mg/m2 can be successfully used 
in combination with radiotherapy (10). Furthermore, as preclinical studies showed that even 
lower doses of gemcitabine effectively radiosensitize cells for up to 72 hours (15, 16), several 
trials were carried out to test lower gemcitabine doses in clinical settings. Specifically, 
gemcitabine (twice a week) in combination with radiotherapy (and no CDDP) was well 
tolerated by patients with MIBC (17). The maximum tolerated dose (MTD) was 27 mg/m2 
twice a week with 60 Gy delivered to the bladder over 6 weeks.  
As the optimal CCRT should contain CDDP, and gemcitabine potentially radiosensitizes 
bladder cancer cells, we decided to conduct a phase I trial in which patients with initially 
operable MIBC were treated with gemcitabine twice/week concomitantly with CDDP and 
radiotherapy.  
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Methods and Materials 
 
Our local institutional review board approved the protocol, and written informed consent was 
obtained from all patients. This study was registered at ClinicalTrials.gov, number 
NCT00556621. 
 
Study design and endpoints 
 
This was a Phase I dose-finding study to determine the MTD and to record acute and late 
toxicity following CCRT with gemcitabine and CDDP in patients with operable MIBC. The 
MTD was defined as the gemcitabine dose associated with dose-limiting toxicity (DLT) 
occurring in 3 out of 6 patients or in 2 out of 3 patients (in this case, an accrual of 3 more 
patients to the previous dose level was planned). 
DLT was defined as: grade 2 or higher pulmonary toxicity, according to the third version of 
the Common Toxicity Criteria for Adverse Events scale (CTCAE 3.0); all other non-
hematological grade 3 or higher CTCAE 3.0 adverse events (except nausea and vomiting); 
grade 4 thrombocytopenia, grade 3 thrombocytopenia lasting more than seven days or 
complicated by hemorrhage; grade 4 neutropenia for more than seven days, febrile 
neutropenia or severe infection. 
 
 
Patients’ selection 
 
Only patients with histologically confirmed MIBC after macroscopically complete 
transurethral resection of the bladder tumor (TURBT) were enrolled. A second TURBT was 
carried out if residual microscopic tumor cells were detected around the primary tumor site. 
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At diagnosis, a CT scan of the chest, abdomen and pelvis and a bone scan were performed to 
rule out metastatic disease and to stage the tumor in all patients. The pretreatment evaluation 
included a physical examination and routine laboratory tests, including complete blood cell 
count, electrolyte, blood urea nitrogen, creatinine and glucose levels and liver function. 
Inclusion criteria were: pT2-pT4a MIBC with microscopically complete resection after the 
first or second TURBT; no macroscopically visible lesions in the pelvic nodes (N0) or distant 
metastases (M0); absence of carcinoma in situ (CIS); no hydronephrosis; (v) Karnofsky 
performance score ≥ 70%; life expectancy ≥ 6 months; adequate bone marrow reserve 
(defined as: pretreatment absolute neutrophil count ≥ 1500/µL, hemoglobin level ≥ 10 g/dL, 
and platelet count ≥ 100,000/µL);  creatinine clearance ≥ 60 mL/min; bilirubin and AST ≤ 3 
and 4 times the institutional upper limits of normal, respectively); age ≥ 18 years; signed 
informed consent form. 
Pregnant or breast-feeding patients were excluded as well as patients with previous 
radiotherapy or chemotherapy treatments (except anterior intra-bladder treatment for localized 
CIS), or history of malignancies other than adequately treated basal cell or squamous cell skin 
cancer or in situ cervical carcinoma.  
 
Treatment plan 
 
The treatment was started within eight weeks after complete TURBT.  
 
Radiotherapy 
Patients underwent CT-based virtual simulation using 2.5 mm thick slices obtained at 2.5 mm 
intervals. Patients were treated in a supine position with empty bladder.  
During the first CCRT part a fractionated dose of 45 Gy (1.8 Gy/fraction/day in 25 fractions, 
over five weeks) was administered to the small pelvis (from S1-S2 to the obturator foramen or 
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the ischiatic tuberosity in case of bladder neck or prostatic urethra invasion) using a 4-field 
box technique. The clinical target volume included the bladder, the obturators and the internal 
and external iliac lymph nodes. During the second CCRT part, 18 Gy (1.8 Gy/fraction/day in 
10 fractions, over two weeks) were delivered to a clinical target volume limited to the initial 
tumor volume, using reduced-box or opposed lateral or antero-posterior fields. A 1.5-cm 
margin was added to the clinical target volume to allow for geometric uncertainties (planning 
target volume). 
Patients were treated with 18 MV photon beams. Dose prescription was in accordance with 
the ICRU 62 report for each patient. 
 
Cisplatin (CDDP) 
CDDP was given at a dose of 20 mg/m²/day by continuous iintravenous.v. infusion during 4 
consecutive days (from day 2 to day 5 and from day 23 to day 26 during the first CCRT part 
and from day 2 to 5 of the second CCRT part). Patients were hydrated and received anti-
emetic drugs according to our in-house protocol. 
 
Gemcitabine 
Gemcitabine was administered intravenously in 50–100 mL of normal saline over 30 min 2 to 
6 hours prior to irradiation and two times a week, on day 2, 5, 9, 12, 16, 19, 23, 26, 30 and 33 
(first CCRT part) and on day 2, 5, 9 and 12 (second CCRT part).  
The starting gemcitabine dose was 15 mg/m² twice/week with planned dose escalation of 5 
mg/m² every two weeks unless the MTD was reached. Dose escalation was not allowed in the 
same patient.  
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Dose modification 
Dose adjustments were based on the weekly absolute neutrophil count (ANC) and platelet 
count, assessed no later than 36 hours before the gemcitabine infusion and on the clinical 
assessment of non-hematological toxicities. Gemcitabine dose was not modified if the ANC 
was > 1000/µL and/or the platelet count was > 100,000/µL. In the case of an ANC between 
500 and 1000/µL and a platelet count between 50,000 and 100,000/µL, gemcitabine was not 
administered. In the case of an even lower ANC or platelet count, chemotherapy was 
definitively stopped.  
Reduction of the creatinine clearance level between 40 and 60 mL/min entailed a 50% 
decrease of the CDDP dose. In the case of even lower values, CDDP was stopped for the 
entire course.  
If a DLT occurred, chemotherapy was stopped, but radiotherapy could be continued based on 
the investigator’s assessment. 
 
Follow-up, toxicity and response evaluation 
 
During treatment, patients were seen weekly at the Radiation Oncology Department and 
weight, toxicity and complete blood count (including blood cell differential and platelet count 
twice a week before each gemcitabine injection) were recorded.  
An evaluation by cystoscopy and TURBT under general anesthesia was performed during the 
third week after the end of the first CCRT part. Complete response (CR) was defined as the 
absence of any macroscopic or microscopic lesion confirmed by the pathologist. In the case of 
residual disease, total cystectomy was proposed to the patient. In the case of CR, the second 
CCRT part was started as soon as possible and no later than four weeks from the completion 
of the first cycle. The final evaluation was done by cystoscopy and TURBT six to eight weeks 
after CCRT completion. 
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After the end of the treatment, patients were clinically assessed every month for the first four 
months and then once every six months (clinical examination, CT scan with contrast and 
cystoscopy). 
 
Statistical analysis 
 
Data were analyzed using the STATA software version 8.0 (Stata Corporation, College 
Station, TX, USA). Survival probabilities were estimated using the actuarial or the Kaplan-
Meier method and the following definitions. 
Overall survival (OS): the event was death from any cause. The time to OS was the interval 
between treatment initiation and death, or the most recent follow-up if no event occurred. 
Disease-specific survival (DSS): the event was death attributable to bladder cancer. The time 
to DSS was the interval between treatment initiation and death from bladder cancer, or the 
most recent follow-up if no event occurred. 
Bladder-intact survival (BIS): the event was cystectomy for any reason or death from any 
cause. The time to BIS was the interval between treatment initiation and cystectomy or death 
(whichever was shorter), or the most recent follow-up if no event occurred. 
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Results 
 
Patients’ characteristics and response to treatment 
 
Fourteen patients with a median age of 72 years (range 51-83) were included in this study 
between June 2005 and June 2009. The patients’ characteristics are listed in Table 1. 
One patient was excluded from the protocol on day 5 of the first CCRT cycle due to poor 
compliance (intravenous drip pulled out and aggressive behavior). He was then treated off-
protocol with radiotherapy (total dose: 63 Gy; complete response after the first cycle) and 
CDDP alone (modified dose of 40 mg/m²/day on day 23 and 24 of the first cycle and on day 2 
and 3 of the second cycle). He was included in the follow-up assessment (“intent-to-treat” 
approach). 
All patients received the first radiotherapy part (45 Gy) and 12 patients (86%) completed the 
whole radiotherapy protocol (45 Gy + 18 Gy). Nine patients (64%) completed the whole 
CCRT course with gemcitabine and CDDP. 
At the TURBT evaluation after the first CCRT part, ten patients showed CR (71% of the 
included patients). One patient had stable disease and underwent cystectomy. Two patients 
(14%) had progressive disease: one underwent cystectomy and the other (who refused radical 
surgery) continued with the second CCRT part with CR at the end of the treatment. One 
patient (7%) could not be evaluated (excluded from the protocol). 
The intact bladder preservation rate was 86% for all included patients (12 out of 14 patients). 
 
Toxicity 
 
Table 2 reports the acute adverse events that occurred outside the radiation field and could 
thus be considered as related to chemotherapy. They were mainly hematological disorders, 
10 
 
digestive alterations and asthenia. Only two of these adverse events were considered as DLT 
(grade 4 thrombocytopenia and grade 3 asthenia). Table 3 reports the adverse events due to 
radiotherapy in the 14 patients. As expected, urinary discomfort and diarrhea were the two 
main acute adverse events. No in-field severe events (to be considered as DLT) were 
observed. Table 4 details the gemcitabine dose, the time of appearance of toxicity, the toxicity 
grade and DLT leading to chemotherapy delay. DLT was confirmed in two patients. One was 
a grade 4 thrombocytopenia at day 16 after four injections of 30 mg/m² gemcitabine and one 
4-day continuous infusion of CDDP. Chemotherapy was stopped, and the patient 
spontaneously recovered. CR was achieved after radiotherapy alone. The second DLT 
occurred at day 26 and consisted of an overall alteration of the performance status, arrhythmia 
(auricular fibrillation) and global edema. The patient had already received eight injections of 
30 mg/m² gemcitabine and two 4-day continuous infusions of CDDP. Only radiotherapy was 
continued and CR was achieved. 
 
Follow-up and survival 
 
The median follow-up was 53 months (4.4 years) for the whole cohort. Two patients died of 
progressive metastatic disease. One died of metastatic disease after salvage cystectomy for 
progressive local disease during the first CCRT part. The second one died of metastatic 
disease in the first year although the tumor was locally controlled. 
Four patients died of undercurrent diseases. One patient died of an ischemic stroke after 
treatment completion, another of metastatic breast disease and the other two from 
cardiovascular disease. 
The median OS for all patients was 5.8 years. The actuarial OS rates were 79% (at 2 years), 
71% (3 years) and 62% (5 years). The median DSS was not reached, but the actuarial DSS 
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rate was 77% at five years. The median BIS was 5.8 years for all patients. The actuarial BIS 
rates were 64% at three years and 56% at five years (Fig.1). 
The nine patients who received the whole CCRT protocol had a median OS of 5.8 years, a 5-
year actuarial DSS rate of 89% and SIB of 89% (at three years) and 76% (five years). 
No salvage cystectomy for local tumor recurrence or toxicity was performed during the 
follow-up period and no significant long-term late toxicity occurred during the follow-up. 
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Discussion 
 
CCRT with CDDP is the most studied protocol for the conservative management of MIBC. 
Although other systemic drugs (such as 5-FU, taxanes, or gemcitabine) have been already 
added to CDDP to increase local control, the combination of fractionated pelvic radiotherapy, 
CDDP and gemcitabine administered twice weekly was has never been tested before. 
We present here the long-term results of our phase I study to assess gemcitabine as a potent 
radiosensitizer in combination with CDDP for the conservative management of MIBC. A 
standard 3+3 Phase I dose escalation schedule was planned as no data was available on the 
twice-weekly gemcitabine and CDDP combination as radiosensitizers. A long-term follow-up 
of our patients was required as gemcitabine may potentially increase late toxicity, when 
combined with pelvic radiotherapy. However, the observed toxicity was acceptable with just 
one grade four thrombocytopenia and one grade four asthenia considered as DLT. No in-field 
severe event occurred. Regarding the efficacy, our long-term results are quite similar to 
previously published data in this setting (18, 19). Indeed, among patients that received the 
complete treatment, BIS was 76% at five years and the median OS was 69.6 months.  
Another phase I trial combining gemcitabine and RT with long-term results has been already 
published, but the pelvic fields were not treated thus making difficult any comparison (20). As 
usually performed, especially in the trials of the Radiation Therapy Oncology Group (21), we 
included the pelvic lymph nodes in the radiation field because lymph node involvement is 
about 20% and 40% in pT2 and pT3 tumors, respectively (22). Another phase I study 
including pelvic fields with gemcitabine reported high toxicity rates and had to be amended to 
a de-escalation study, with a 25 mg/m² decrease at each level (23). Consequently, the toxicity 
observed in this phase I trial should absolutely be interpreted by taking into account this large 
radiation volume that increases the risk of interactions between ionizing radiation, 
gemcitabine and CDDP.  
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Kent et al. conducted a phase I study on gemcitabine given twice weekly without CDDP and 
with 60 Gy of radiation after TURBT (17). DLT included deep venous thrombosis, diarrhea, 
abnormal liver function tests and edema. The recommended dose in this trial was 27 mg/m2 
twice-weekly, which is close to the MTD found in our study (25 mg/m² given twice-weekly).  
Besides, Caffo et al. performed a phase I study on conservative radiotherapy with weekly 
gemcitabine and 100 mg/m2 CDDP every three weeks (18). Starting with 200 mg/m2/week 
gemcitabine, they escalated the dose up to 500 mg/m2/week, with two DLT: one death and 
one intestinal perforation. The gemcitabine recommended dose of 400 mg/m2/week was then 
evaluated in a phase II study that was unfortunately prematurely closed due to low accrual. 
The radiotherapy dose was 54 Gy (1.8 Gy/fraction) in both trials. A pooled analysis of the two 
trials on 26 patients was published in 2010 with a median follow-up of 74 months (24). The 5-
year clinical outcomes were a 70.1% OS rate, a 78.9% DSS rate and a 73.8% BIS rate. 
Although this association was effective as all evaluable patients were disease-free at the time 
of the cystoscopic evaluation, concerns regarding toxicity with the weekly gemcitabine 
schedule remain. Indeed, intestinal toxicities in the phase I study and neutropenia in the phase 
II study frequently occurred (even after omission of the gemcitabine injection at day 15 and 
36) and for that reason we chose a twice-weekly schedule allowing for lower doses of 
gemcitabine. 
In our study, we used standard radiotherapy fractionation (1.8 Gy/fraction/day 5 days a week). 
However, another group studied gemcitabine radiosensitization with hypofractionated chemo-
radiotherapy (52.5 Gy in 20 fractions over 28 days) in a phase I study and found a MTD of 
100 mg/m2 when delivered only once a week and without CDDP (25). The consecutive phase 
II trial included 50 patients with transitional cell carcinoma staged T2-3 N0 M0 (19). All 
patients completed the radiotherapy course; 46 (92%) tolerated all four gemcitabine cycles. 
Two patients stopped after two cycles, and two after three cycles, due to bowel toxicity. 
Forty-four (88%) achieved a complete endoscopic response. At a median follow-up of 36 
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months (range, 15- 62 months), 36 patients were alive and 32 had a functional and intact 
bladder. By using Kaplan-Meier analyses, the 3-year cancer-specific survival was 82%, and 
OS was 75%. Nevertheless, these results were obtained with hypofractionated conformal 
radiotherapy that used a four-field plan with multi-leaf collimators, delivered to the whole 
bladder and a minimum 1.5-cm margin. Finally, these regimens are clearly manageable for 
patients with comorbidities but we are still convinced that CDDP presents a strong added-
value in fit patients.  
The results presented here allowed us to determine the gemcitabine MTD when given twice a 
week in combination with CDDP and radiotherapy. Although bladder preservation and 
disease control results are promising, this remains a phase I study with only 14 patients and a 
further validation in a larger cohort is needed. In view of these findings, a French phase II 
randomized multi-institutional trial named GETUG V04 started in 2011 to assess the efficacy 
and tolerability of this new combination strategy with gemcitabine twice-weekly compared to 
the standard CCRT schedule with CDDP alone (NCT01495676). 
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Figure legends 
Fig. 1  Survival curves obtained using the Kaplan-Meier method for the overall survival 
(OS), disease-specific survival (DSS) and bladder-intact survival (BIS). 
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Combined Chemo-radiotherapy with Twice-weekly Gemcitabine and 
Cisplatin for Organ Preservation in Muscle-invasive Bladder Cancer: 
Long-term Results of a Phase I Trial  
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Summary 
Concomitant treatment with cisplatin and radiotherapy (CCRT) remains the gold standard for 
bladder preservation in the case of muscle-invasive bladder cancer. We evaluated the benefit 
of adding gemcitabine given twice a week to the standard CCRT. Among the patients who 
received the complete treatment, bladder-intact survival was 76% at 5 years and the median 
overall survival was 69.6 months. The gemcitabine maximum tolerated dose was 25 mg/m². 
Bladder preservation and disease control were promising. 
 
Abstract 
Purpose: Concomitant treatment with radiotherapy and cisplatin (CDDP) remains the gold 
standard for bladder preservation in the case of muscle-invasive bladder cancer (MIBC). We 
present the long-term results of a phase I clinical trial to assess the association of twice-
weekly gemcitabine with CDDP and radiotherapy in this setting.  
Methods and Materials: Patients with pT2-pT4 N0 M0 MIBC without hydronephrosis or 
diffuse carcinoma in situ were enrolled in this study. After maximal transurethral resection of 
the bladder tumor, patients received concomitantly radiotherapy (63 Gy in 1.8 fractions) and 
chemotherapy (20 mg CDDP /m²/day over 4 days every 21 days; and gemcitabine twice a 
week). The starting dose of gemcitabine was 15 mg/m² with dose escalation to 20, 25 and 30 
*BLINDED Revised Manuscript (Unmarked)
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mg/m². The primary endpoint was the maximum tolerated dose (MTD). Secondary endpoints 
included toxicity and tumor control. 
Results: Fourteen patients were enrolled. Dose-limiting toxicity (DLT) occurred in two 
patients treated with 30 mg/m² gemcitabine (grade 4 thrombocytopenia and severe 
impairment of the WHO performance status, respectively). Nine patients received the 
complete chemo-radiotherapy protocol. The recommended dose of gemcitabine was 25 
mg/m². The median follow-up was 53 months, and the overall and disease-specific 5-year 
survival rates were 62% and 77%, respectively. Among the patients who received the 
complete treatment, bladder-intact survival was 76% at 5 years and the median overall 
survival was 69.6 months. 
Conclusions: This regimen was well-tolerated. The gemcitabine MTD was 25 mg/m². 
Bladder preservation and disease control were promising. A multicenter phase II randomized 
trial is ongoing. 
 
Keywords: bladder cancer; chemo-radiotherapy; gemcitabine; cisplatin; organ preservation 
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Introduction 
 
Concurrent chemo-radiotherapy (CCRT) for muscle-invasive transitional cell bladder cancer 
(MIBC) is an acceptable option for patients who are medically unfit for radical surgery as 
well as for patients initially selected for cystectomy. The standard CCRT includes a cisplatin 
(CDDP)-containing regimen and is associated with cystectomy-free survival rates between 
42% and 55% at 5 years, depending on the initial tumor stage (1-6).  
Gemcitabine has been shown to be effective in treating bladder cancer in combination with 
CDDP in neoadjuvant and metastatic settings (7, 8). In addition, gemcitabine has significant 
radiosensitizing activity in various cancer cell lines (9, 10), including those derived from 
bladder tumors (11). The effectiveness of gemcitabine-based CCRT has been widely reported 
for many different epithelial tumors (12, 13). Gemcitabine sensitizing activity occurs at sub-
cytotoxic doses, and the mechanism involves depletion of the deoxyribonucleoside 
triphosphate pools, particularly deoxyadenosine triphosphate (dATP) (14). Consecutive 
studies confirmed that weekly doses ranging from 150 to 450 mg/m2 can be successfully used 
in combination with radiotherapy (10). Furthermore, as preclinical studies showed that even 
lower doses of gemcitabine effectively radiosensitize cells for up to 72 hours (15, 16), several 
trials were carried out to test lower gemcitabine doses in clinical settings. Specifically, 
gemcitabine (twice a week) in combination with radiotherapy (and no CDDP) was well 
tolerated by patients with MIBC (17). The maximum tolerated dose (MTD) was 27 mg/m2 
twice a week with 60 Gy delivered to the bladder over 6 weeks.  
As the optimal CCRT should contain CDDP, and gemcitabine potentially radiosensitizes 
bladder cancer cells, we decided to conduct a phase I trial in which patients with initially 
operable MIBC were treated with gemcitabine twice/week concomitantly with CDDP and 
radiotherapy.  
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Methods and Materials 
 
Our local institutional review board approved the protocol, and written informed consent was 
obtained from all patients. This study was registered at ClinicalTrials.gov, number 
NCT00556621. 
 
Study design and endpoints 
 
This was a Phase I dose-finding study to determine the MTD and to record acute and late 
toxicity following CCRT with gemcitabine and CDDP in patients with operable MIBC. The 
MTD was defined as the gemcitabine dose associated with dose-limiting toxicity (DLT) 
occurring in 3 out of 6 patients or in 2 out of 3 patients (in this case, an accrual of 3 more 
patients to the previous dose level was planned). 
DLT was defined as: grade 2 or higher pulmonary toxicity, according to the third version of 
the Common Toxicity Criteria for Adverse Events scale (CTCAE 3.0); all other non-
hematological grade 3 or higher CTCAE 3.0 adverse events (except nausea and vomiting); 
grade 4 thrombocytopenia, grade 3 thrombocytopenia lasting more than seven days or 
complicated by hemorrhage; grade 4 neutropenia for more than seven days, febrile 
neutropenia or severe infection. 
 
 
Patient selection 
 
Only patients with histologically confirmed MIBC after macroscopically complete 
transurethral resection of the bladder tumor (TURBT) were enrolled. A second TURBT was 
carried out if residual microscopic tumor cells were detected around the primary tumor site. 
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At diagnosis, a CT scan of the chest, abdomen and pelvis and a bone scan were performed to 
rule out metastatic disease and to stage the tumor in all patients. The pretreatment evaluation 
included a physical examination and routine laboratory tests, including complete blood cell 
count, electrolyte, blood urea nitrogen, creatinine and glucose levels and liver function. 
Inclusion criteria were: pT2-pT4a MIBC with microscopically complete resection after the 
first or second TURBT; no macroscopically visible lesions in the pelvic nodes (N0) or distant 
metastases (M0); absence of carcinoma in situ (CIS); no hydronephrosis; (v) Karnofsky 
performance score ≥ 70%; life expectancy ≥ 6 months; adequate bone marrow reserve 
(defined as: pretreatment absolute neutrophil count ≥ 1500/µL, hemoglobin level ≥ 10 g/dL, 
and platelet count ≥ 100,000/µL);  creatinine clearance ≥ 60 mL/min; bilirubin and AST ≤ 3 
and 4 times the institutional upper limits of normal, respectively); age ≥ 18 years; signed 
informed consent form. 
Pregnant or breast-feeding patients were excluded as well as patients with previous 
radiotherapy or chemotherapy treatments (except anterior intra-bladder treatment for localized 
CIS), or history of malignancies other than adequately treated basal cell or squamous cell skin 
cancer or in situ cervical carcinoma.  
 
Treatment plan 
 
The treatment was started within eight weeks after complete TURBT.  
 
Radiotherapy 
Patients underwent CT-based virtual simulation using 2.5 mm thick slices obtained at 2.5 mm 
intervals. Patients were treated in a supine position with empty bladder.  
During the first CCRT part a fractionated dose of 45 Gy (1.8 Gy/fraction/day in 25 fractions, 
over five weeks) was administered to the small pelvis (from S1-S2 to the obturator foramen or 
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the ischiatic tuberosity in case of bladder neck or prostatic urethra invasion) using a 4-field 
box technique. The clinical target volume included the bladder, the obturators and the internal 
and external iliac lymph nodes. During the second CCRT part, 18 Gy (1.8 Gy/fraction/day in 
10 fractions, over two weeks) were delivered to a clinical target volume limited to the initial 
tumor volume, using reduced-box or opposed lateral or antero-posterior fields. A 1.5-cm 
margin was added to the clinical target volume to allow for geometric uncertainties (planning 
target volume). 
Patients were treated with 18 MV photon beams. Dose prescription was in accordance with 
the ICRU 62 report for each patient. 
 
Cisplatin (CDDP) 
CDDP was given at a dose of 20 mg/m²/day by continuous intravenous infusion during 4 
consecutive days (from day 2 to day 5 and from day 23 to day 26 during the first CCRT part 
and from day 2 to 5 of the second CCRT part). Patients were hydrated and received anti-
emetic drugs according to our in-house protocol. 
 
Gemcitabine 
Gemcitabine was administered intravenously in 50–100 mL of normal saline over 30 min 2 to 
6 hours prior to irradiation and two times a week, on day 2, 5, 9, 12, 16, 19, 23, 26, 30 and 33 
(first CCRT part) and on day 2, 5, 9 and 12 (second CCRT part).  
The starting gemcitabine dose was 15 mg/m² twice/week with planned dose escalation of 5 
mg/m² every two weeks unless the MTD was reached. Dose escalation was not allowed in the 
same patient.  
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Dose modification 
Dose adjustments were based on the weekly absolute neutrophil count (ANC) and platelet 
count, assessed no later than 36 hours before the gemcitabine infusion and on the clinical 
assessment of non-hematological toxicities. Gemcitabine dose was not modified if the ANC 
was > 1000/µL and/or the platelet count was > 100,000/µL. In the case of an ANC between 
500 and 1000/µL and a platelet count between 50,000 and 100,000/µL, gemcitabine was not 
administered. In the case of an even lower ANC or platelet count, chemotherapy was 
definitively stopped.  
Reduction of the creatinine clearance level between 40 and 60 mL/min entailed a 50% 
decrease of the CDDP dose. In the case of even lower values, CDDP was stopped for the 
entire course.  
If a DLT occurred, chemotherapy was stopped, but radiotherapy could be continued based on 
the investigator’s assessment. 
 
Follow-up, toxicity and response evaluation 
 
During treatment, patients were seen weekly at the Radiation Oncology Department and 
weight, toxicity and complete blood count (including blood cell differential and platelet count 
twice a week before each gemcitabine injection) were recorded.  
An evaluation by cystoscopy and TURBT under general anesthesia was performed during the 
third week after the end of the first CCRT part. Complete response (CR) was defined as the 
absence of any macroscopic or microscopic lesion confirmed by the pathologist. In the case of 
residual disease, total cystectomy was proposed to the patient. In the case of CR, the second 
CCRT part was started as soon as possible and no later than four weeks from the completion 
of the first cycle. The final evaluation was done by cystoscopy and TURBT six to eight weeks 
after CCRT completion. 
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After the end of the treatment, patients were clinically assessed every month for the first four 
months and then once every six months (clinical examination, CT scan with contrast and 
cystoscopy). 
 
Statistical analysis 
 
Data were analyzed using the STATA software version 8.0 (Stata Corporation, College 
Station, TX, USA). Survival probabilities were estimated using the actuarial or the Kaplan-
Meier method and the following definitions. 
Overall survival (OS): the event was death from any cause. The time to OS was the interval 
between treatment initiation and death, or the most recent follow-up if no event occurred. 
Disease-specific survival (DSS): the event was death attributable to bladder cancer. The time 
to DSS was the interval between treatment initiation and death from bladder cancer, or the 
most recent follow-up if no event occurred. 
Bladder-intact survival (BIS): the event was cystectomy for any reason or death from any 
cause. The time to BIS was the interval between treatment initiation and cystectomy or death 
(whichever was shorter), or the most recent follow-up if no event occurred. 
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Results 
 
Patients’ characteristics and response to treatment 
 
Fourteen patients with a median age of 72 years (range 51-83) were included in this study 
between June 2005 and June 2009. The patients’ characteristics are listed in Table 1. 
One patient was excluded from the protocol on day 5 of the first CCRT cycle due to poor 
compliance (intravenous drip pulled out and aggressive behavior). He was then treated off-
protocol with radiotherapy (total dose: 63 Gy; complete response after the first cycle) and 
CDDP alone (modified dose of 40 mg/m²/day on day 23 and 24 of the first cycle and on day 2 
and 3 of the second cycle). He was included in the follow-up assessment (“intent-to-treat” 
approach). 
All patients received the first radiotherapy part (45 Gy) and 12 patients (86%) completed the 
whole radiotherapy protocol (45 Gy + 18 Gy). Nine patients (64%) completed the whole 
CCRT course with gemcitabine and CDDP. 
At the TURBT evaluation after the first CCRT part, ten patients showed CR (71% of the 
included patients). One patient had stable disease and underwent cystectomy. Two patients 
(14%) had progressive disease: one underwent cystectomy and the other (who refused radical 
surgery) continued with the second CCRT part with CR at the end of the treatment. One 
patient (7%) could not be evaluated (excluded from the protocol). 
The intact bladder preservation rate was 86% for all included patients (12 out of 14 patients). 
 
Toxicity 
 
Table 2 reports the acute adverse events that occurred outside the radiation field and could 
thus be considered as related to chemotherapy. They were mainly hematological disorders, 
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digestive alterations and asthenia. Only two of these adverse events were considered DLT 
(grade 4 thrombocytopenia and grade 3 asthenia). Table 3 reports the adverse events due to 
radiotherapy in the 14 patients. As expected, urinary discomfort and diarrhea were the two 
main acute adverse events. No in-field severe events (to be considered as DLT) were 
observed. Table 4 details the gemcitabine dose, the time of appearance of toxicity, the toxicity 
grade and DLT leading to chemotherapy delay. DLT was confirmed in two patients. One was 
a grade 4 thrombocytopenia at day 16 after four injections of 30 mg/m² gemcitabine and one 
4-day continuous infusion of CDDP. Chemotherapy was stopped, and the patient 
spontaneously recovered. CR was achieved after radiotherapy alone. The second DLT 
occurred at day 26 and consisted of an overall alteration of the performance status, arrhythmia 
(auricular fibrillation) and global edema. The patient had already received eight injections of 
30 mg/m² gemcitabine and two 4-day continuous infusions of CDDP. Only radiotherapy was 
continued and CR was achieved. 
 
Follow-up and survival 
 
The median follow-up was 53 months (4.4 years) for the whole cohort. Two patients died of 
progressive metastatic disease. One died of metastatic disease after salvage cystectomy for 
progressive local disease during the first CCRT part. The second one died of metastatic 
disease in the first year although the tumor was locally controlled. 
Four patients died of undercurrent diseases. One patient died of an ischemic stroke after 
treatment completion, another of metastatic breast disease and the other two from 
cardiovascular disease. 
The median OS for all patients was 5.8 years. The actuarial OS rates were 79% (at 2 years), 
71% (3 years) and 62% (5 years). The median DSS was not reached, but the actuarial DSS 
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rate was 77% at five years. The median BIS was 5.8 years for all patients. The actuarial BIS 
rates were 64% at three years and 56% at five years (Fig.1). 
The nine patients who received the whole CCRT protocol had a median OS of 5.8 years, a 5-
year actuarial DSS rate of 89% and SIB of 89% (at three years) and 76% (five years). 
No salvage cystectomy for local tumor recurrence or toxicity was performed during the 
follow-up period and no significant long-term late toxicity occurred during the follow-up. 
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Discussion 
 
CCRT with CDDP is the most studied protocol for the conservative management of MIBC. 
Although other systemic drugs (such as 5-FU, taxanes, or gemcitabine) have been already 
added to CDDP to increase local control, the combination of fractionated pelvic radiotherapy, 
CDDP and gemcitabine administered twice weekly has never been tested. 
We present here the long-term results of our phase I study to assess gemcitabine as a potent 
radiosensitizer in combination with CDDP for the conservative management of MIBC. A 
standard 3+3 Phase I dose escalation schedule was planned as no data was available on the 
twice-weekly gemcitabine and CDDP combination as radiosensitizers. A long-term follow-up 
of our patients was required as gemcitabine may potentially increase late toxicity, when 
combined with pelvic radiotherapy. However, the observed toxicity was acceptable with just 
one grade four thrombocytopenia and one grade four asthenia considered as DLT. No in-field 
severe event occurred. Regarding the efficacy, our long-term results are quite similar to 
previously published data in this setting (18, 19). Indeed, among patients that received the 
complete treatment, BIS was 76% at five years and the median OS was 69.6 months.  
Another phase I trial combining gemcitabine and RT with long-term results has been already 
published, but the pelvic fields were not treated thus making difficult any comparison (20). As 
usually performed, especially in the trials of the Radiation Therapy Oncology Group (21), we 
included the pelvic lymph nodes in the radiation field because lymph node involvement is 
about 20% and 40% in pT2 and pT3 tumors, respectively (22). Another phase I study 
including pelvic fields with gemcitabine reported high toxicity rates and had to be amended to 
a de-escalation study, with a 25 mg/m² decrease at each level (23). Consequently, the toxicity 
observed in this phase I trial should absolutely be interpreted by taking into account this large 
radiation volume that increases the risk of interactions between ionizing radiation, 
gemcitabine and CDDP.  
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Kent et al. conducted a phase I study on gemcitabine given twice weekly without CDDP and 
with 60 Gy of radiation after TURBT (17). DLT included deep venous thrombosis, diarrhea, 
abnormal liver function tests and edema. The recommended dose in this trial was 27 mg/m2 
twice-weekly, which is close to the MTD found in our study (25 mg/m² given twice-weekly).  
Caffo et al. performed a phase I study on conservative radiotherapy with weekly gemcitabine 
and 100 mg/m2 CDDP every three weeks (18). Starting with 200 mg/m2/week gemcitabine, 
they escalated the dose up to 500 mg/m2/week, with two DLT: one death and one intestinal 
perforation. The gemcitabine recommended dose of 400 mg/m2/week was then evaluated in a 
phase II study that was unfortunately prematurely closed due to low accrual. The radiotherapy 
dose was 54 Gy (1.8 Gy/fraction) in both trials. A pooled analysis of the two trials on 26 
patients was published in 2010 with a median follow-up of 74 months (24). The 5-year 
clinical outcomes were a 70.1% OS rate, a 78.9% DSS rate and a 73.8% BIS rate. Although 
this association was effective as all evaluable patients were disease-free at the time of the 
cystoscopic evaluation, concerns regarding toxicity with the weekly gemcitabine schedule 
remain. Indeed, intestinal toxicities in the phase I study and neutropenia in the phase II study 
frequently occurred (even after omission of the gemcitabine injection at day 15 and 36) and 
for that reason we chose a twice-weekly schedule allowing for lower doses of gemcitabine. 
In our study, we used standard radiotherapy fractionation (1.8 Gy/fraction/day 5 days a week). 
However, another group studied gemcitabine radiosensitization with hypofractionated chemo-
radiotherapy (52.5 Gy in 20 fractions over 28 days) in a phase I study and found a MTD of 
100 mg/m2 when delivered only once a week and without CDDP (25). The consecutive phase 
II trial included 50 patients with transitional cell carcinoma staged T2-3 N0 M0 (19). All 
patients completed the radiotherapy course; 46 (92%) tolerated all four gemcitabine cycles. 
Two patients stopped after two cycles, and two after three cycles, due to bowel toxicity. 
Forty-four (88%) achieved a complete endoscopic response. At a median follow-up of 36 
months (range, 15- 62 months), 36 patients were alive and 32 had a functional and intact 
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bladder. By using Kaplan-Meier analyses, the 3-year cancer-specific survival was 82%, and 
OS was 75%. Nevertheless, these results were obtained with hypofractionated conformal 
radiotherapy that used a four-field plan with multi-leaf collimators, delivered to the whole 
bladder and a minimum 1.5-cm margin. Finally, these regimens are clearly manageable for 
patients with comorbidities but we are still convinced that CDDP presents a strong added-
value in fit patients.  
The results presented here allowed us to determine the gemcitabine MTD when given twice a 
week in combination with CDDP and radiotherapy. Although bladder preservation and 
disease control results are promising, this remains a phase I study with only 14 patients and a 
further validation in a larger cohort is needed. In view of these findings, a French phase II 
randomized multi-institutional trial named GETUG V04 started in 2011 to assess the efficacy 
and tolerability of this new combination strategy with gemcitabine twice-weekly compared to 
the standard CCRT schedule with CDDP alone (NCT01495676). 
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Figure legends 
Fig. 1  Survival curves obtained using the Kaplan-Meier method for the overall survival 
(OS), disease-specific survival (DSS) and bladder-intact survival (BIS). 
 
 
 
 
Table 1 Patient characteristics  
Characteristic n (%) 
Sex 
 
male 11 (79) 
female 3 (21) 
Age   
median 72 
range 51-83 
Histologic grade   
poorly differenciated 10 (71) 
moderately differenciated 3 (21) 
unknown 1 (7) 
TNM stage 
 
T2 12 (86) 
T4 2 (14) 
N0 14 (100) 
M0 14 (100) 
Gemcitabine biweekly dose (mg/m²)   
 15 3 (21) 
20 3 (21) 
25 6 (43) 
30 2 (14) 
 
 
Table 1
Table 2 Acute adverse events occurring outside the radiation fields  
 
 
 
Toxicity type Grade 0, n (%) Grade 1, n (%) Grade 2, n (%) Grade 3, n (%) Grade 4, n (%) 
Thrombopenia 1 (7.1) 7 (50) 4 (28.6) 1 (7.1) 1 (7.1) 
Neutropenia 5 (35.7) 3 (21.4) 2 (14.3) 4 (28.6) 0 (0) 
Anemia 5 (35.7) 7 (50) 2 (14.3) 0 (0) 0 (0) 
Infection 12 (85.7) 1 (7.1) 1 (7.1) 0 (0) 0 (0) 
Renal  12 (85.7) 1 (7.1) 1 (7.1) 0 (0) 0 (0) 
Pulmonary  12 (85.7) 1 (7.1) 1 (7.1) 0 (0) 0 (0) 
Fever 12 (85.7) 0 (0) 2 (14.3) 0 (0) 0 (0) 
Nausea 6 (42.9) 7 (50) 0 (0) 1 (7.1) 0 (0) 
Vomiting 11 (78.6) 1 (7.1) 2 (14.3) 0 (0) 0 (0) 
Dyspnea 13 (92.9) 1 (7.1) 0 (0) 0 (0) 0 (0) 
Asthenia 3 (21.4) 6 (42.9) 4 (28.6) 1 (7.1) 0 (0) 
Insomnia 13 (92.9) 1 (7.1) 0 (0) 0 (0) 0 (0) 
Anorexia 12 (85.7) 1 (7.1) 1 (7.1) 0 (0) 0 (0) 
Hepatic  12 (85.7) 0 (0) 2 (14.3) 0 (0) 0 (0) 
Cutaneous  13 (92.9) 1 (7.1) 0 (0) 0 (0) 0 (0) 
Auditive  14 (100) 0 (0) 0 (0) 0 (0) 0 (0) 
Neurologic 14 (100) 0 (0) 0 (0) 0 (0) 0 (0) 
Table 2
Table 3 Acute adverse events occurring within the radiation fields 
 
 
Toxicity type Grade 0, n (%) Grade 1, n (%) Grade 2, n (%) Grade 3, n (%) Grade 4, n (%) 
Urinary incontinence 11 (78.6) 2 (15.4) 1 (7.1) 0 (0) 0 (0) 
Urination retention 13 (92.9) 0 (0) 1 (7.1) 0 (0) 0 (0) 
Hematuria 12 (85.7) 1 (7.1) 0 (0) 0 (0) 0 (0) 
Dysuria 11 (78.6) 3 (21.4) 0 (0) 0 (0) 0 (0) 
Pollakiuria 13 (92.9) 0 (0) 1 (7.1) 0 (0) 0 (0) 
Diarrhea 9 (64.3) 2 (15.4) 3 (21.4) 0 (0) 0 (0) 
Dyserection 10 (90.9) 0 (0) 1 (9.1) 0 (0) 0 (0) 
Cutaneous  13 (92.9) 1 (7.1) 0 (0) 0 (0) 0 (0) 
Table 3
Table 4 Toxicity appearance time and dose-limiting toxicity (DLT) confirmation 
 
 
 
 
 
 
 
 
Patient 
number 
Biweekly 
gemcitabine 
dose 
Day since treatment 
initiation 
Toxicity grade Toxicity type 
Dose-limiting 
toxicity 
1 15 23 3 neutropenia No 
2 15 16 1 thrombopenia No 
2 15 19 1 thrombopenia No 
4 20 23 3 neutropenia No 
5 20 16 2 thrombopenia No 
6 20 12 2 infection No 
6 20 16 2 infection No 
6 20 19 2 infection No 
9 25 12 1 thrombopenia No 
9 25 16 2 thrombopenia No 
9 25 19 1 thrombopenia No 
9 25 33 1 thrombopenia No 
10 30 16 4 thrombopenia Yes 
11 30 26 3 asthenia Yes 
12 25 16 3 thrombopenia No 
12 25 19 2 thrombopenia No 
12 25 23 1 thrombopenia No 
12 25 26 1 thrombopenia No 
12 25 30 1 thrombopenia No 
12 25 33 1 thrombopenia No 
13 25 23 2 neutropenia No 
13 25 26 2 neutropenia No 
14 25 16 2 thrombopenia No 
14 25 19 2 thrombopenia No 
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